Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02109445 · ClinicalTrials.gov registry record · Phase 2
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02109445 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 3 participants.
The verdict
NCT02109445, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously treated with anticancer therapies.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG PF-03084014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-09-03 |
| Est. Completion | 2014-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109445
The ClinicalTrials.gov registry entry for NCT02109445 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02109445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02109445 about?
NCT02109445 is a clinical study titled "Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies". This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients w...
What is the current status of trial NCT02109445?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-09-03. Estimated completion is 2014-11-06.
What interventions are being tested in trial NCT02109445?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), PF-03084014 (DRUG).
Who is sponsoring clinical trial NCT02109445?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.